Please upgrade your browser.
Radical vs partial nephrectomy
Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma (RCC)...
The study, known as RECORD-3, was published online July 21 in the Journal of Clinical Oncology.
The supposedly independent agency harassed the administration's political opponents and saved its health-care law.
The new study, published online this week in Nature, was led by Celeste Simon, PhD, a professor of Cell and Developmental Biology and the scientific director for the Abramson Family Cancer Research Institute at Penn.
Patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC) may derive significant survival benefit from cytoreductive nephrectomy (CN), particularly if their initial prognosis is good, study findings indicate.
Patients with renal cell carcinoma tumours larger than 4 cm benefit from undergoing elective partial nephrectomy (PN) rather than radical nephrectomy (RN) surgery, a study has found.
By Michael B. Lawing, member Kidney Cancer Association board of directors, and kidney cancer survivor
Dr. Andre Khalil of the University of Maine, studying breast cancer and Dr. Leif Oxburgh from Maine Medical Center Research Institute, studying kidney cancer, each received nearly $180,000 to further their research.
An enzyme called FBP1 -- essential for regulating metabolism -- binds to a transcription factor in the nucleus of certain kidney cells and restrains energy production in the cell body, researchers report.
|Powered by NeonCRM|